Targeting the premetastatic niche:epigenetic therapies in the spotlight

作     者：Vivien Low John Blenis Ana P.Gomes Vivien Low;John Blenis;Ana P.Gomes

作者机构：Meyer Cancer CenterWeill Cornell MedicineNew YorkNYUSA Department of PharmacologyWeill Cornell MedicineNew YorkNYUSA 

出 版 物：《Signal Transduction and Targeted Therapy》 (信号转导与靶向治疗（英文）)

年 卷 期：2020年第5卷第1期

页      面：1871-1872页

核心收录：

学科分类：0710[理学-生物学] 1002[医学-临床医学] 1001[医学-基础医学(可授医学、理学学位)] 100214[医学-肿瘤学] 10[医学] 

基　　金：A.P.G.is supported by a Susan G.Komen Postdoctoral Fellowship and a Pathway to Independence Award from NCI(K99CA218686) NIH Grants RO1GM51405,RO1CA46595 and RO3CA212562 provide research support for the Blenis laboratory 

主　　题：metastatic epigenetic al 

摘      要：The treatment of metastatic cancers remains a challenge in the clinic,with recurrences persisting at high rates even after surgical resection of primary *** the perseverance of circulating tumor cells after resection,this phenomenon is abetted by the formation of the premetastatic niche(PMN),a distant environment ripe for the colonization of new metastases,which is conditioned by factors and extracellular vesicles secreted by the primary *** their recent paper,Lu et *** how such PMNs in the lung can be disrupted by low-dose adjuvant epigenetic therapy,and propose a novel therapeutic avenue to supplement tumor resection.